To evaluate the additive effects of the novel CRIM1 rs3821169 variant relative to the well-known NUDT15 and TPMT pharmacogenetic effects, GVB-based ROC analyses were performed before and after introducing the homozygous CRIM1 rs3821169 variant for the entire cohort of 320 pediatric ALL patients (Fig. 3 and Additional file 1: Figures S1–S3). Here, CRIM1 is linked to acute lymphoblastic leukemia.